Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC and Envafolimab in HER2+ Biliary Tract Cancer
NCT05417230Phase 2Unknown
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin in biliary tract cancer (BTC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05417230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417230.